ArticleJournal of translational medicine2014
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.
Article in Journal of translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Flow Cytometric Profiling of Peripheral Immune Checkpoints Predicts Prognosis and Reveals PD-1/Treg/IL-10 Crosstalk in B-Cell Lymphoma.ImmunoTargets and therapy · 2025Article
- MicroRNAs as Key Players in Melanoma Cell Resistance to MAPK and Immune Checkpoint Inhibitors.International journal of molecular sciences · 2020Review
- A Novel Probe for Spliceosomal Proteins that Induces Autophagy and Death of Melanoma Cells Reveals New Targets for Melanoma Drug Discovery.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2019Article
- Targeting the cross-talk between Urokinase receptor and Formyl peptide receptor type 1 to prevent invasion and trans-endothelial migration of melanoma cells.Journal of experimental & clinical cancer research : CR · 2017Article
- Phenotype characterization of human melanoma cells resistant to dabrafenib.Oncology reports · 2017Article
- microRNA-625 inhibits tumorigenicity by suppressing proliferation, migration and invasion in malignant melanoma.Oncotarget · 2017Article
- Protein expression changes induced in a malignant melanoma cell line by the curcumin analogue compound D6.BMC cancer · 2016Article
- Phenylethanoid Glycosides fromJournal of Cancer · 2016Article
- Novel therapeutic mechanisms determine the effectiveness of lipid-core nanocapsules on melanoma models.International journal of nanomedicine · 2016Article
- Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets.Frontiers in oncology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 20 institutions in 9 countries.
Funding
Abstract
The fourth "Melanoma Bridge Meeting" took place in Naples, December 5 to 8th, 2013. The four topics discussed at this meeting were: Diagnosis and New Procedures, Molecular Advances and Combination Therapies, News in Immunotherapy, and Tumor Microenvironment and Biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.